TY - JOUR
T1 - Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis
T2 - Insights From THAOS
AU - THAOS Investigators
AU - Caponetti, Angelo Giuseppe
AU - Rapezzi, Claudio
AU - Gagliardi, Christian
AU - Milandri, Agnese
AU - Dispenzieri, Angela
AU - Kristen, Arnt V.
AU - Wixner, Jonas
AU - Maurer, Mathew S.
AU - Garcia-Pavia, Pablo
AU - Tournev, Ivailo
AU - Planté-Bordeneuve, Violaine
AU - Chapman, Douglass
AU - Amass, Leslie
AU - van Cleemput, Johan
AU - Waddington-Cruz, Marcia
AU - Schmidt, Hartmut
AU - Dillmann, Klaus Ulrich
AU - Mølgaard, Henning
AU - Moreno, Juan Gonzalez
AU - Costello, Jose Gonzalez
AU - Beamud, Francisco Munoz
AU - Davila, Lucia Galan
AU - Adams, David
AU - Inamo, Jocelyn
AU - Lairez, Olivier
AU - Vita, Giuseppe
AU - Merlini, Giampaolo
AU - Cirami, Calogero Lino
AU - Luigetti, Marco
AU - Emdin, Michele
AU - Sekijima, Yoshiki
AU - Jeon, Eun Seok
AU - Oh, Jeeyoung
AU - Gonzalez Duarte Briseno, Maria Alejandra
AU - Nienhuis, Hans
AU - Coelho, Teresa
AU - Conceicao, Isabel
AU - Azevedo, Olga
AU - Badelita, Sorina
AU - Press, Rayomand
AU - Parman, Yesim
AU - Shah, Sanjiv
AU - Quan, Dianna
AU - Marburger, Tessa
AU - Polydefkis, Michael
AU - Witteles, Ronald
AU - Gottlieb, Stephen
AU - Sarswat, Nitasha
AU - Drachman, Brian
AU - Tauras, James
N1 - Funding Information:
The THAOS registry and this analysis were sponsored by Pfizer. Medical writing support was provided by Joshua Fink, PhD, of Engage Scientific Solutions and funded by Pfizer. Dr Rapezzi has received research grants from Pfizer and consultancy fees from Pfizer; Alnylam, and Prothena. Dr Milandri has received consultancy fees from Alnylam. Dr. Dispenzieri has received research grants from Celgene, Millennium, Pfizer, Janssen, and Alnylam; funding from Pfizer for meeting expenses (travel); and attended advisory boards for Akcea and Intellia. Dr Kristen has received research support from and advisory board attendance for Pfizer. Dr Wixner has received consulting fees, travel support for lectures, and advisory boards from Pfizer, Akcea, and Alnylam. Dr Maurer has received grants and/or personal fees from Akcea, Alnylam, Eidos, GlaxoSmithKline, Ionis, Pfizer, and Prothena. Dr Garcia-Pavia has received speaker and/or consulting fees from Pfizer, Eidos, Alnylam, Prothena, Neurimmune, and Akcea; and research funding from Alnylam and Pfizer. Dr Tournev has received sponsorship from Pfizer for participation in advisory boards, congresses, and conferences. Dr Planté-Bordeneuve is serving as a medical advisor for Pfizer, Alnylam, Eidos, and Ionis. Drs Chapman and Amass are full-time employees of Pfizer and hold stock and/or stock options with Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Funding Information:
The authors thank all THAOS patients and investigators for their important contributions to this study. They also thank Rajiv Mundayat, Jan Kiszko and Denise Rill for their contributions to earlier versions of this work. Additional THAOS investigators contributing to this analysis: Johan van Cleemput, Afdeling Klinische Cardiologie, O&N I, Leuven, Belgium; Marcia Waddington-Cruz, Hospital Universitario Clementino Fraga Filho, Rio de Janeiro, Brazil; Hartmut Schmidt, Transplant Hepatology, Universitatsklinikum M?nster, M?nster, Germany; Klaus-Ulrich Dillmann, Universit?tsklinikum des Saarlandes, Homburg, Germany; Henning M?lgaard, Aarhus University Hospital, Skejby, Aarhus, Denmark; Juan Gonzalez Moreno, Hospital Son Llatzer, Palma de Mallorca, Spain; Jose Gonzalez Costello, Hospital Universitari de Bellvitge, Barcelona, Spain; Francisco Munoz Beamud, Hospital Juan Ramon Jimenez, Huelva, Spain; Lucia Galan Davila, Hospital Clinico San Carlos, Madrid, Spain; David Adams, Centre Hospitalier Universitaire de Bicetre, France; Jocelyn Inamo, Centre Hospitalier Universitaire, Fort de France, France; Olivier Lairez, Centre Hospitalier Universitaire de Toulouse?Hopital Rangueil, Toulouse, France; Giuseppe Vita, Azienda Ospedaliero Universitaria Policlinico G. Martino, Messina, Italy; Giampaolo Merlini, Centro per lo Studio e la Cura delle Amiloidosi Sistemiche, Pavia, Italy; Calogero Lino Cirami, Azienda Ospedaliero-Universitaria di Careggi, Florence, Italy; Marco Luigetti, Fondazione Policlinico Gemelli, Universita Cattolica Del Sacro Cuore, Rome, Italy; Michele Emdin, Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanita Pubblica, Pisa, Italy; Yoshiki Sekijima, Shinshu University School of Medicine, Matsumoto, Japan; Eun-Seok Jeon, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Jeeyoung Oh, Konkuk University Medical Center, Seoul, Republic of Korea; Maria Alejandra Gonzalez Duarte Briseno, Instituto Nacional de Ciencia Medicas y Nutricion Salvador Zubiran, Distrito Federal, Mexico; Hans Nienhuis, University Medical Center Groningen, Groningen, the Netherlands; Teresa Coelho, Unidade Clinica de Paramiloidose?Centro Hospitalar Porto, EPE?Hospital Geral Santo Antonio, Porto, Portugal; Isabel Conceicao, Hospital Santa Maria, Lisbon, Portugal; Olga Azevedo, Centro Hospitalar Do Alto Ave, EPE, Guimaraes, Portugal; Sorina Badelita, Institutul de Cardiologie C. C. Iliescu, Bucharest, Romania; Rayomand Press, Karolinska University Hospital, Huddinge, Stockholm, Sweden; Yesim Parman, Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey; Sanjiv Shah, Northwestern University, Chicago, Illinois, USA; Dianna Quan, University of Colorado Denver, Aurora, Colorado, USA; Tessa Marburger, Oregon Health and Science University, Portland, Oregon, USA; Michael Polydefkis, Johns Hopkins Hospital, Baltimore, Maryland, USA; Ronald Witteles, Stanford University School of Medicine, Stanford, California, USA; Stephen Gottlieb, University of Maryland, Baltimore, Maryland, USA; Nitasha Sarswat, University of Chicago Medical Center, Chicago, Illinois, USA; Brian Drachman, University of Pennsylvania?Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, USA; David Steidley, Mayo Clinic Arizona, Phoenix, Arizona, USA; Scott Hummel, University of Michigan, Ann Arbor, Michigan, USA; David Slosky, Vanderbilt University School of Medicine, Nashville, Tennessee, USA; Daniel Jacoby, Smilow Cancer Hospital at Yale?New Haven, New Haven, Connecticut, USA; Jose Nativi-Nicolau, University of Utah Health Sciences Center, Salt Lake City, Utah, USA; James Tauras, Montefiore Medical Center?Jack D. Weiler Hospital, New York, New York, USA; Sasa Zivkovic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA; Jose Tallaj, University of Alabama at Birmingham, Birmingham, Alabama, USA; Daniel Lenihan, Washington University School of Medicine, St Louis, Missouri, USA.
Publisher Copyright:
© 2021 The Authors
PY - 2021/10
Y1 - 2021/10
N2 - Objectives: Because patients with ATTRv cardiomyopathy are more likely to be male, this analysis aimed to increase information on associations between sex and genotype, phenotype, and degree of myocardial involvement in ATTRv amyloidosis. Background: Transthyretin amyloid cardiomyopathy is a progressive, fatal disease that occurs due to accumulation of wild-type or variant (ATTRv) transthyretin amyloid fibrils in the myocardium. Methods: The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing global longitudinal observational survey of patients with ATTR amyloidosis and asymptomatic carriers with TTR mutations. Data from THAOS (data cutoff: January 6, 2020) were analyzed to determine any sex-based differences in genotype, phenotype, and presence of cardiac and neurological symptoms in patients with ATTRv amyloidosis and in patients with ATTRv amyloidosis and cardiomyopathy. Results: There were 2,790 patients with ATTRv amyloidosis enrolled in THAOS, with male patients more likely to have symptoms of cardiac involvement and a cardiac phenotype. Male prevalence was greater in patients with more severe cardiac manifestations of disease, as assessed with N-terminal pro–B-type natriuretic peptide, left-ventricular (LV) ejection fraction, mean LV wall thickness divided by height, and LV mass index divided by height. Sex, age at disease onset, and genotype category were identified by multivariate analyses as risk factors for the development of cardiomyopathy (defined as increased LV septum thickness divided by height). Conclusions: In this analysis, myocardial involvement was more frequent and pronounced in male patients with ATTRv amyloidosis, suggesting that there may be biological characteristics that inhibit myocardial amyloid infiltration in females or facilitate it in males.
AB - Objectives: Because patients with ATTRv cardiomyopathy are more likely to be male, this analysis aimed to increase information on associations between sex and genotype, phenotype, and degree of myocardial involvement in ATTRv amyloidosis. Background: Transthyretin amyloid cardiomyopathy is a progressive, fatal disease that occurs due to accumulation of wild-type or variant (ATTRv) transthyretin amyloid fibrils in the myocardium. Methods: The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing global longitudinal observational survey of patients with ATTR amyloidosis and asymptomatic carriers with TTR mutations. Data from THAOS (data cutoff: January 6, 2020) were analyzed to determine any sex-based differences in genotype, phenotype, and presence of cardiac and neurological symptoms in patients with ATTRv amyloidosis and in patients with ATTRv amyloidosis and cardiomyopathy. Results: There were 2,790 patients with ATTRv amyloidosis enrolled in THAOS, with male patients more likely to have symptoms of cardiac involvement and a cardiac phenotype. Male prevalence was greater in patients with more severe cardiac manifestations of disease, as assessed with N-terminal pro–B-type natriuretic peptide, left-ventricular (LV) ejection fraction, mean LV wall thickness divided by height, and LV mass index divided by height. Sex, age at disease onset, and genotype category were identified by multivariate analyses as risk factors for the development of cardiomyopathy (defined as increased LV septum thickness divided by height). Conclusions: In this analysis, myocardial involvement was more frequent and pronounced in male patients with ATTRv amyloidosis, suggesting that there may be biological characteristics that inhibit myocardial amyloid infiltration in females or facilitate it in males.
KW - ATTRv amyloidosis
KW - myocardial involvement
KW - registry
KW - sex
UR - http://www.scopus.com/inward/record.url?scp=85115175807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115175807&partnerID=8YFLogxK
U2 - 10.1016/j.jchf.2021.05.005
DO - 10.1016/j.jchf.2021.05.005
M3 - Article
C2 - 34391735
AN - SCOPUS:85115175807
SN - 2213-1779
VL - 9
SP - 736
EP - 746
JO - JACC: Heart Failure
JF - JACC: Heart Failure
IS - 10
ER -